Radiogenomics in Interventional Oncology

Curr Oncol Rep. 2021 Jan 2;23(1):9. doi: 10.1007/s11912-020-00994-9.


Purpose of review: Radiogenomics is a growing field that has garnered immense interest over the past decade, owing to its numerous applications in the field of oncology and its potential value in improving patient outcomes. Current applications have only begun to delve into the potential of radiogenomics, and particularly in interventional oncology, there is room for development and increased value of these applications.

Recent findings: The field of interventional oncology (IO) has seen valuable radiogenomic applications, from prediction of response to locoregional therapies in hepatocellular carcinoma to identification of genetic mutations in non-small cell lung cancer. Future directions that can increase the value of radiogenomics include applications that address tumor heterogeneity, predict immune responsiveness of tumors, and differentiate between oligoprogression and early widespread progression, among others. Radiogenomics, whether in terms of methodologies or applications, is still in the early stages of development and far from maturation. Future applications, particularly in the field of interventional oncology, will allow realization of its full potential.

Keywords: Artificial intelligence; Hepatocellular carcinoma; Interventional oncology; Non-small cell lung cancer; Radiogenomics; Radiomics.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / radiotherapy
  • Radiation Genomics*
  • Radiation Oncology*